Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 755 participants.

Also called NCT04218266

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 755 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04218266
  • EudraCT 2019-002365-35
Other papers using this trial's data
  • Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study Lancet (London, England), 2022-04-09 DOI, PubMed 35385695

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Austria, Belgium, Canada, Czechia, France, Hungary, Italy, Japan, Latvia, Netherlands, Spain, Sweden, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04218266. Randomized; quadruple masking; primary purpose treatment. Start 2020-01-30 (actual); primary completion 2021-10-08 (actual). Results posted on 2022-10-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.
Acronym
PACIFIC-AF
Condition
Atrial Fibrillation (AF)
Intervention (Drug)
BAY2433334
Intervention (Drug)
Apixaban
Intervention (Other)
BAY2433334 matching placebo
Intervention (Other)
Apixaban matching placebo
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct04218266
Content hash
c7ec23bf445dbdc5bd6e399ea13fa22060f74e41e27145a284cc1cbb3d488f9b